Alto Neuroscience Q2 2024 Earnings Report

Alto Neuroscience EPS Results

• Actual EPS: -$0.60
• Consensus EPS: -$0.67
• Beat/Miss: Beat by +$0.07
• One Year Ago EPS: N/A

Alto Neuroscience Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Alto Neuroscience Announcement Details

• Quarter: Q2 2024
• Date: 8/13/2024
• Time: TAS
• Conference Call Date: Tuesday, August 13, 2024
• Conference Call Time: 4:00PM ET

Alto Neuroscience (NYSE:ANRO) (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies. By partnering with biopharmaceutical companies and academic institutions, the company seeks to de-risk clinical trials, reduce time to market and enhance go-to-market strategies for novel psychiatric medications. Ongoing collaborations focus on validating biomarkers and expanding the platform’s utility across multiple neuropsychiatric indications.

Formed in the late 2010s and headquartered in New York, Alto Neuroscience has assembled a leadership team with deep expertise in neuroscience, drug development and data analytics. Under the direction of co-founder and Chief Executive Officer Marshall Brennan, the company has initiated multiple clinical programs in the United States and Europe. Alto continues to expand its global footprint through strategic partnerships and joint research agreements.

As a publicly traded company on the New York Stock Exchange, Alto Neuroscience is positioned at the intersection of digital health and psychiatry. Its mission is to transform the standard of care for neuropsychiatric patients by delivering predictive tools that enable more personalized, effective treatments.